Phase I Study of Afatinib and Selumetinib in Patients with KRAS‐Mutated Colorectal, Non‐Small Cell Lung, and Pancreatic Cancer

LESSONS LEARNED: Afatinib and selumetinib can be combined in continuous and intermittent dosing schedules, albeit at lower doses than approved for monotherapy. Maximum tolerated dose for continuous and intermittent schedules is afatinib 20 mg once daily and selumetinib 25 mg b.i.d. Because the antic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: van Brummelen, Emilie M.J., Huijberts, Sanne, van Herpen, Carla, Desar, Ingrid, Opdam, Frans, van Geel, Robin, Marchetti, Serena, Steeghs, Neeltje, Monkhorst, Kim, Thijssen, Bas, Rosing, Hilde, Huitema, Alwin, Beijnen, Jos, Bernards, Rene, Schellens, Jan
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018304/
https://ncbi.nlm.nih.gov/pubmed/33296125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13631
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados